• RotaChrom CPC Instruments & Solutions
  • Technology
  • About Us
  • FAQ
  • Blog
  • Webinars
  • Podcasts
  • Pressroom
  • Contact
Here you can see the logo of RotaChrom Technologies.
Here you can see the logo of RotaChrom Technologies.
  • Products
    • CPC Modeler
    • GMP rCPC
    • rCPC
    • iCPC
    • Continuous CPC
    • pCPC
    • SKIDS
  • Pricing
  • Technology
  • Applications
    • Pharma and biotech
    • Cosmetics and Fragrances
    • Food and Beverages
    • Botanical applications
  • Calculator
  • Company
    • About Us
    • Events
  • Resources
    • Blog
    • Webinars
    • Publications
    • Pressroom
    • FAQ
    • Podcasts
  • Contact
    • Career
    • Contact
    • Book a meeting

RotaChrom Technologies partners with Cyclolab to increase production of COVID-19 treatment

Here you can see an iCPC instrument.
February 9, 2021
In News, Studies
Share via Share via Share via Share via

New Partnership Aims to Develop More Efficient, Cost-Effective Process to Purify Remdesivir.

RotaChrom announced the launch of a collaboration with Cyclolab Cyclodextrin Research and Development Laboratory Ltd. (“Cyclolab”), a cyclodextrin research, development and manufacturing company. The strategic partnership between Cyclolab and RotaChrom aims to develop a more efficient and cost-effective process to purify Remdesivir, which is a widely used treatment option for COVID-19.

Remdesivir, an inhibitor of the viral RNA-dependent, RNA polymerase, is a direct-acting antiviral agent that is approved by the FDA as a treatment for patients with severe cases of COVID-19. It was originally developed to treat the Ebola virus, but research was also conducted on its effectiveness as a treatment for COVID-19 as a result of the pandemic. Once it was shown to be effective in clinical trials of hospitalized patients with severe symptoms, the agent was approved and is now being used in the United States, as well as other countries around the world. The formulations of Remdesivir contain 3 percent of the active ingredient and 97 percent of the cyclodextrin derivative that serves as an excipient.

The partnership will combine RotaChrom’s scalable CPC technology with Cyclolab’s knowledge and experience with cyclodextrins. The scalable system that will be utilized for this collaboration includes RotaChrom’s pilot-scale centrifugal partition chromatographic, known as the rCPC, that utilizes an innovative methodology of chromatography where separation occurs between two immiscible liquid phases, offering several advantages compared to more traditional methods. The result is a more purified compound of interest at a lower cost due to increased efficiency and automation.

“While the world anxiously waits for COVID-19 vaccines to be distributed, many are already infected and suffering from this terrible virus,” said RotaChrom CEO László Madarász. “By enhancing the production of a proven drug that has the ability to treat those who are already sick, we could potentially improve lives. We are proud to provide a solution by combining our company’s technologies with Cyclolab to create this much-needed strategic partnership.”

Cyclolab is a company with unparalleled expertise in the manufacturing, design and formulation of cyclodextrins. For this new collaboration, Cyclolab will provide its cyclodextrin-related analytical, formulation and chemistry expertise that spans back to the 1970s. In the three-staged collaboration that kicked off in early 2021, Cyclolab and RotaChrom aim to explore the potential synergies of the companies’ technologies and evaluate how a more economic purification alternative could be discovered.

“Cyclolab is a pioneer and a global leader in cyclodextrin science, and we are delighted to be working with RotaChrom, a unique company with state-of-the-art chromatography capabilities,” said Tamás Sohajda, CEO of Cyclolab. “This strategic collaboration is a tremendous opportunity to create novel discoveries leading to significant added value through pharmaceutical therapies. While there are a handful of published examples on the marriage of these two techniques, no one has ever attempted to bring it to the industrial level. This is our goal now and what can be a better compound to start with than the one that is critically needed in millions of doses? If we could make even a small impact on better availability – either logistically or economically – we would consider it as a huge success and a beginning of a new era in preparative chromatography.”

Previous article
Centrifugal partition chromatography vs. Legacy chromatography
Next article
Technology & investment considerations for industrial scale purification

Related News

Other posts that you should not miss.

Enhancing Chromatographic Goals: An In-Depth Look at CPC and the pCPC Platform

November 2, 2023
-
Education, News
Achieving effective separation, isolation, and remediation through chromatography is of paramount importance. This article delves into the world of Centrifugal Partition Chromatography (CPC), exploring its unique approach to…
Read More →
2 MIN READ

Advanced Chromatography – Arrangement of CPC

November 22, 2022
-
Education, News
In our previous blog series, ‘An Introduction to Chromatography’, we examined the essential, core aspects of chromatography. In ‘Advanced Chromatography’ we focus on Centrifugal Partition Chromatography (CPC) and…
Read More →
3 MIN READ

Industrial-Scale API Production (Part 2)

June 25, 2023
-
Education, News
The production of small molecule Active Pharmaceutical Ingredients (APIs) is a complex and intricate process that demands specialized facilities, regulatory expertise, chemistry know-how, and efficient supply chain management.…
Read More →
2 MIN READ

Latest News

Advancing Separation Science: CPC Device Installation and Its Impact

April 17, 2025 – News

RotaChrom at Flow Chemistry Europe 2025: Exploring Innovation Through CPC Technology

April 16, 2025 – Events, News

SZTE’s Award-Winning Innovation: A Natural Breakthrough in Obesity Prevention

February 4, 2025 – Education, News, Studies

Innovations in Chiral Purification: Exploring Techniques and Future Potential

January 31, 2025 – Download, Education, News

Webinars

Separation of Remdesivir Diastereomeres by Centrifugal Partition Chromatography

September 25, 2023

Green Features of Centrifugal Partition Chromatography

May 10, 2021

Contact Us

RotaChrom Technologies PLC (Headquarters)

Csillag street 2/A, Kecskemet, HU-6000

+36 70 885 6922

RotaChrom North America Inc.

300 Spectrum Center Drive, Irvine, CA 92618

+1 (720) 220-5669

Cookie Policy  /  Data Protection Policy  /  RotaChrom® is a registered trademark of Rotachrom Technologies in the USA and EU. / © 2025 RotaChrom Technologies. All rights reserved.
RotaChrom partners with Cyclolab to increase Remdesivir production.